British Biotech Gets $15M as its Armed Oncolytic Virus Enters the Clinic

PsiOxus will receive a generous milestone payment from Bristol-Myers Squibb, which licenses the biotech’s oncolytic virus technology.

PsiOxus hopes to become the world’s leading immuno-oncolytic company, systemically administering “gene therapy for tumors.” Today, the biotech has announced that its Clinical Trial Application for NG-348 for the treatment of solid tumors, has been approved. Under the terms of a deal signed back in December 2016, Bristol-Myers Squibb will pay PsiOxus $15M (€13M) in milestones, which could rise to $936M (€795M) if all goes well with the product’s development and commercialization.

PsiOxus’ viruses can be enhanced by “arming” them with new genes that produce antibodies, cytokines, immunomodulatory proteins, or nucleotide-based weapons to help them to kill cancer cells. John Beadle, CEO of PsiOxus, let us in on what else is different about his company’s viruses: “Essentially, the virus has lost a number of genes that are necessary to replicate within normal cells but not in the tumor cells.”

Elsewhere, Transgene has put on somewhat of a comeback, with the company now starting a Phase I/IIa trial to test its ‘next generation’ oncolytic virus against glioblastoma. German biotech Oryx has already tested its ParvOryx virus against glioblastoma, and will also investigate it as part of a combination therapy.


Image – nobeatsofierce / shutterstock.com

Previous post

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

Next post

How Biotech Could Change Your Christmas Dinner

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.